<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VES</journal-id>
<journal-id journal-id-type="hwp">spves</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Endovascular Surg</journal-id>
<journal-title>Vascular and Endovascular Surgery</journal-title>
<issn pub-type="ppub">1538-5744</issn>
<issn pub-type="epub">1938-9116</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1538574413492390</article-id>
<article-id pub-id-type="publisher-id">10.1177_1538574413492390</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Outcomes and Complications of Sclerotherapy for Venous Malformations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Yajing</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Hui</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lin</surname>
<given-names>Xiaoxi</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
<xref ref-type="corresp" rid="corresp1-1538574413492390"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Xiaojie</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Yunbo</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Gang</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1538574413492390">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1538574413492390">
<label>1</label>Department of Plastic &amp; Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China</aff>
<author-notes>
<corresp id="corresp1-1538574413492390">Xiaoxi Lin, Department of Plastic &amp; Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, People’s Republic of China. Email: <email>linxiaoxi@126.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>6</issue>
<fpage>454</fpage>
<lpage>461</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objective:</title>
<p>To determine the efficacy of sclerotherapy for venous malformations (VMs).</p>
</sec>
<sec>
<title>Methods:</title>
<p>PubMed was used to search the medical literatures for publication on the combined topics of “VMs and sclerotherapy.” The final evaluation of the venous lesions was based on both objective parameters and subjective parameters. Complications were also recorded.</p>
</sec>
<sec>
<title>Results:</title>
<p>A total of 35 studies published between 1986 and 2011 matched the selection criteria and were included. Ethanol, polidocanol, ethanolamine oleate, and sodium tetradecyl sulfate (STS) are the 4 mainstream sclerosants. The total efficiency of these 4 sclerosants all exceeded 90% except STS. Skin damage (10.0%) was the most common minor complication. Other complications included renal damage (3.9%), nerve damage (1.85%), muscle damage (0.66%), pulmonary embolism (0.25%), cardiovascular collapse (0.08%), and others.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Sclerotherapy is effective for VMs. However, there is limited evidence from randomized clinical trials to support the use of any kinds of sclerosants.</p>
</sec>
</abstract>
<kwd-group>
<kwd>sclerotherapy</kwd>
<kwd>embolization</kwd>
<kwd>endovascular</kwd>
<kwd>venous malformations</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1538574413492390">
<title>Introduction</title>
<p>Venous malformations (VMs) are common vascular malformations that may be located in any region of the body, with a preference for head and neck.<sup>
<xref ref-type="bibr" rid="bibr1-1538574413492390">1</xref>
</sup> Not all VMs need to be treated, as most of them are asymptomatic. However, quite a few patients have functional and esthetical problems brought by this congenital disorder.<sup>
<xref ref-type="bibr" rid="bibr2-1538574413492390">2</xref>
</sup>
</p>
<p>Surgical excision is one of the traditional treatments of VMs; however, symptom recurrence always occurs, as complete excision is seldom performed. Hence, percutaneous sclerotherapy as a less-invasive treatment has gradually taken the place of surgical excision to become the mainstay of treatment for VMs with good mid-term results in the past 2 decades. Many kinds of sclerosants have been reported on treating VMs. Although each sclerosant has a different mechanism of action causing varying amounts of success and complications, they all result in a thrombus that incorporates erythrocytes, organizing, and subsequent contraction and recanalization, with the consequent regression of the lesion.<sup>
<xref ref-type="bibr" rid="bibr3-1538574413492390">3</xref>
</sup> An ideal sclerosant should meet the criteria that it is effective in endothelial cells and has low toxicity in the surrounding tissues. In this study, we reviewed the therapeutic results and safety of sclerotherapy in patients with VMs using different sclerosants. With the help of this systematic review, we aim to determine the efficacy of sclerotherapy for VMs and to assess the relationship of different sclerosants to response and the adverse effect profile.</p>
</sec>
<sec id="section2-1538574413492390" sec-type="methods">
<title>Methods</title>
<p>PubMed was used to search the medical literatures for publication on the combined topics of “venous malformation and sclerotherapy” using the following key words: “venous malformation,” “low-flow vascular malformation,” “vascular malformation,” “sclerotherapy,” “embolization,” “endovascular,” “percutaneous,” and “NOT arteriovenous.” Finally, the results were combined with the key words “treatment” or “therapy”. Search took place in January 2012.</p>
<p>All the studies should meet the following inclusion criteria: (1) randomized controlled studies, cohort studies, or case series; (2) at least 5 patients with VMs treated with sclerotherapy; (3) sclerotherapy was used as the independent therapeutic agent; and (4) original English studies.</p>
<p>The following exclusion criteria were then applied to the patients in each study to eliminate inappropriate patients and produce a homogeneous population amenable to systematic review: (1) case reports, (2) Klippel-Trenaunay syndrome or other syndromes related to VMs, (3) using more than 1 sclerosant or combined with other management, (4) other vascular malformations such as arteriovenous malformation, lymphatic venous malformation, and so on, (5) patients lost to follow-up, and (6) non-English articles.</p>
<p>Two reviewers (Y.Q. and H.C.) independently screened the titles and abstracts of all the articles. Areas of conflicts between the reviewers were subsequently reviewed by a third party (X.L.) and were resolved through consensus. There was 100% agreement on the final interpretation of the data.</p>
<p>Summary tables were constructed for all included articles. The final evaluation of the venous lesions was based on both objective parameters (the volume of the lesion ascertained before and after treatment by ultrasound, fluoroscopy, digital subtraction angiography, magnetic resonance imaging, and so on) and subjective parameters (symptoms and complaints of the patient before and after treatments). The objective outcome was graded as cured (more than 90% reduction in the volume), improved (25%-90% reduction in the volume), and little change or worse (&lt;25% reduction in the volume) at the end of the treatment. The subjective outcome was graded as cured (disappearance of symptoms), improved (relief of symptoms), and little change or worse at the end of the treatment. Complications were classified as skin damage (skin blistering, skin ulcer, skin necrosis, cutaneous fistula, and pigmentation), nerve damage (temporary numbness or paresthesias, transient nerve palsy, and permanent nerve palsy), muscle damage (muscular fibrosis), renal damage (hemoglobinnuria and renal failure), pulmonary embolism, cardiovascular collapse, and others.</p>
</sec>
<sec id="section3-1538574413492390">
<title>Results</title>
<p>Using the above search strategy, 1053 publications were identified in the literature. Of these, 954 studies were excluded after the titles and abstracts were reviewed, and another 64 studies were excluded after the full text was reviewed, including 2 studies<sup>
<xref ref-type="bibr" rid="bibr4-1538574413492390">4</xref>,<xref ref-type="bibr" rid="bibr5-1538574413492390">5</xref>
</sup> in which ethylcellulose was used to gelify ethanol from liquid into gel. Thirty-five articles satisfied our selection criteria for review that were published between 1986 and 2011 (<xref ref-type="fig" rid="fig1-1538574413492390">Figure 1</xref>). Demographic data were collected from each article (<xref ref-type="table" rid="table1-1538574413492390">Table 1</xref>).</p>
<fig id="fig1-1538574413492390" position="float">
<label>Figure 1.</label>
<caption>
<p>Study selection flowchart.</p>
</caption>
<graphic xlink:href="10.1177_1538574413492390-fig1.tif"/>
</fig>
<table-wrap id="table1-1538574413492390" position="float">
<label>Table 1.</label>
<caption>
<p>Quantitative Systematic Review.</p>
</caption>
<graphic alternate-form-of="table1-1538574413492390" xlink:href="10.1177_1538574413492390-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">No.</th>
<th rowspan="2">Study</th>
<th rowspan="2">Year</th>
<th rowspan="2">Country</th>
<th rowspan="2">Intervention</th>
<th rowspan="2">Study Type</th>
<th rowspan="2">Number of patients </th>
<th rowspan="2">Gender (M/F)</th>
<th rowspan="2">Type (diffusing percentage)</th>
<th colspan="4">Location</th>
</tr>
<tr>
<th>H&amp;N</th>
<th>Limbs</th>
<th>Trunk</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td> 1</td>
<td>Spence et al<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref>
</sup>
</td>
<td>2011</td>
<td>Canada</td>
<td>Absolute ethanol</td>
<td>Retrospective cohort</td>
<td>17</td>
<td>N/A</td>
<td>N/A</td>
<td>17</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 2</td>
<td>Orlando et al<sup>
<xref ref-type="bibr" rid="bibr7-1538574413492390">7</xref>
</sup>
</td>
<td>2011</td>
<td>Brazil</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>39</td>
<td>10/29</td>
<td>N/A</td>
<td>0</td>
<td>39</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 3</td>
<td>Baek et al<sup>
<xref ref-type="bibr" rid="bibr8-1538574413492390">8</xref>
</sup>
</td>
<td>2011</td>
<td>Korea</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>22</td>
<td>10/12</td>
<td>N/A</td>
<td>22</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 4</td>
<td>Su et al<sup>
<xref ref-type="bibr" rid="bibr9-1538574413492390">9</xref>
</sup>
</td>
<td>2010</td>
<td>China</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>60</td>
<td>26/34</td>
<td>N/A</td>
<td>60</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 5</td>
<td>Orlando et al<sup>
<xref ref-type="bibr" rid="bibr10-1538574413492390">10</xref>
</sup>
</td>
<td>2010</td>
<td>Brazil</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>81</td>
<td>34/47</td>
<td>N/A</td>
<td>0</td>
<td>69</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td> 6</td>
<td>Ierardi et al<sup>
<xref ref-type="bibr" rid="bibr11-1538574413492390">11</xref>
</sup>
</td>
<td>2010</td>
<td>Italy</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>80</td>
<td>35/45</td>
<td>N/A</td>
<td>0</td>
<td>80</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 7</td>
<td>Lee et al<sup>
<xref ref-type="bibr" rid="bibr12-1538574413492390">12</xref>
</sup>
</td>
<td>2009</td>
<td>Korea</td>
<td>Pure or diluted ethanol</td>
<td>Case series</td>
<td>87</td>
<td>40/47</td>
<td>51.7%</td>
<td>87</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 8</td>
<td>Lee et al<sup>
<xref ref-type="bibr" rid="bibr13-1538574413492390">13</xref>
</sup>
</td>
<td>2005</td>
<td>China</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>5</td>
<td>5/0</td>
<td>N/A</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 9</td>
<td>Rimon et al<sup>
<xref ref-type="bibr" rid="bibr14-1538574413492390">14</xref>
</sup>
</td>
<td>2004</td>
<td>Israel</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>21</td>
<td>6/15</td>
<td>33.3%</td>
<td>2</td>
<td>14</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>Lee et al<sup>
<xref ref-type="bibr" rid="bibr15-1538574413492390">15</xref>
</sup>
</td>
<td>2003</td>
<td>Korea</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>87</td>
<td>N/A</td>
<td>100%</td>
<td align="center" colspan="4">N/A</td>
</tr>
<tr>
<td>11</td>
<td>Johnson et al<sup>
<xref ref-type="bibr" rid="bibr16-1538574413492390">16</xref>
</sup>
</td>
<td>2002</td>
<td>USA</td>
<td>Ethanol</td>
<td>Case series</td>
<td>7</td>
<td>4/3</td>
<td>N/A</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>Shireman et al<sup>
<xref ref-type="bibr" rid="bibr17-1538574413492390">17</xref>
</sup>
</td>
<td>1997</td>
<td>USA</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>11</td>
<td>5/6</td>
<td>45.4%</td>
<td>0</td>
<td>9</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>Berthelsen et al<sup>
<xref ref-type="bibr" rid="bibr18-1538574413492390">18</xref>
</sup>
</td>
<td>1986</td>
<td>Sweden</td>
<td>Absolute ethanol</td>
<td>Case series</td>
<td>5</td>
<td>3/2</td>
<td>N/A</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>Hoque et al<sup>
<xref ref-type="bibr" rid="bibr19-1538574413492390">19</xref>
</sup>
</td>
<td>2011</td>
<td>Bangladesh</td>
<td>5% EO</td>
<td>Case series</td>
<td>84 with 85 lesions</td>
<td>39/44</td>
<td>N/A</td>
<td>52</td>
<td>16</td>
<td>15</td>
<td>2 </td>
</tr>
<tr>
<td>15</td>
<td>Kaji et al<sup>
<xref ref-type="bibr" rid="bibr20-1538574413492390">20</xref>
</sup>
</td>
<td>2009</td>
<td>Japan</td>
<td>5% EO</td>
<td>Case series</td>
<td>73</td>
<td>N/A</td>
<td>N/A</td>
<td>73</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>Johann et al<sup>
<xref ref-type="bibr" rid="bibr21-1538574413492390">21</xref>
</sup>
</td>
<td>2005</td>
<td>Brazil</td>
<td>1.25% or 2.5% EO</td>
<td>Case series</td>
<td>8 with 9 lesions</td>
<td>3/5</td>
<td>N/A</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>17</td>
<td>Kim et al<sup>
<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup>
</td>
<td>2004</td>
<td>Korea</td>
<td>5% EO</td>
<td>Case series</td>
<td>16</td>
<td>6/10</td>
<td>N/A</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>Bonan et al<sup>
<xref ref-type="bibr" rid="bibr23-1538574413492390">23</xref>
</sup>
</td>
<td>2007</td>
<td>Brazil</td>
<td>2.5% MO</td>
<td>Case series</td>
<td>6</td>
<td>3/3</td>
<td>N/A</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>19</td>
<td>Blaise et al<sup>
<xref ref-type="bibr" rid="bibr24-1538574413492390">24</xref>
</sup>
</td>
<td>2011</td>
<td>France</td>
<td>0.25%-3% POL</td>
<td>Case series</td>
<td>19</td>
<td>6/13</td>
<td>68.4%</td>
<td>8</td>
<td>9</td>
<td>1</td>
<td>1 </td>
</tr>
<tr>
<td>20</td>
<td>Yamaki et al<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>
</sup>
</td>
<td>2008</td>
<td>Japan</td>
<td>10% EO</td>
<td>RCT</td>
<td>40</td>
<td>9/31</td>
<td>85.0%</td>
<td>17</td>
<td>18</td>
<td>4</td>
<td>1 </td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>1% POL</td>
<td>
</td>
<td>49</td>
<td>14/35</td>
<td>83.6%</td>
<td>25</td>
<td>16</td>
<td>7</td>
<td>1 </td>
</tr>
<tr>
<td>21</td>
<td>Mimura et al<sup>
<xref ref-type="bibr" rid="bibr26-1538574413492390">26</xref>
</sup>
</td>
<td>2003</td>
<td>Japan</td>
<td>1% POL</td>
<td>Case series</td>
<td>14</td>
<td>6/8</td>
<td>N/A</td>
<td>2</td>
<td>11</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>Cabrera et al<sup>
<xref ref-type="bibr" rid="bibr27-1538574413492390">27</xref>
</sup>
</td>
<td>2003</td>
<td>Spain</td>
<td>0.25%-4% POL</td>
<td>Case series</td>
<td>35</td>
<td>13/22</td>
<td>45.7%</td>
<td>3</td>
<td>23</td>
<td>3</td>
<td>4 </td>
</tr>
<tr>
<td>23</td>
<td>Jain et al<sup>
<xref ref-type="bibr" rid="bibr28-1538574413492390">28</xref>
</sup>
</td>
<td>2002</td>
<td>India</td>
<td>1% POL</td>
<td>Case series</td>
<td>9</td>
<td>N/A</td>
<td>N/A</td>
<td>0</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>24</td>
<td>Marrocco-Trischitta et al<sup>
<xref ref-type="bibr" rid="bibr29-1538574413492390">29</xref>
</sup>
</td>
<td>2001</td>
<td>Italy</td>
<td>1%-3% POL</td>
<td>Case series</td>
<td>9</td>
<td>9/0</td>
<td>N/A</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9 </td>
</tr>
<tr>
<td>25</td>
<td>Yamaki et al<sup>
<xref ref-type="bibr" rid="bibr30-1538574413492390">30</xref>
</sup>
</td>
<td>2000</td>
<td>Japan</td>
<td>3% POL</td>
<td>Case series</td>
<td>28</td>
<td>2/26</td>
<td>N/A</td>
<td>16</td>
<td>8</td>
<td>2</td>
<td>2 </td>
</tr>
<tr>
<td>26</td>
<td>Krokidis et al<sup>
<xref ref-type="bibr" rid="bibr31-1538574413492390">31</xref>
</sup>
</td>
<td>2011</td>
<td>Italy</td>
<td>3% STS</td>
<td>Case reports</td>
<td>5</td>
<td>0/5</td>
<td>N/A</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5 </td>
</tr>
<tr>
<td>27</td>
<td>Khandpur et al<sup>
<xref ref-type="bibr" rid="bibr32-1538574413492390">32</xref>
</sup>
</td>
<td>2010</td>
<td>India</td>
<td>3% STS</td>
<td>Case series</td>
<td>11</td>
<td>5/6</td>
<td>N/A</td>
<td>4</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>28</td>
<td>Tan et al<sup>
<xref ref-type="bibr" rid="bibr33-1538574413492390">33</xref>
</sup>
</td>
<td>2007</td>
<td>Canada</td>
<td>3% STS</td>
<td>Case series</td>
<td>65</td>
<td>22/43</td>
<td>66.1%</td>
<td>0</td>
<td>56</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>29</td>
<td>Mahesh et al<sup>
<xref ref-type="bibr" rid="bibr34-1538574413492390">34</xref>
</sup>
</td>
<td>2003</td>
<td>India</td>
<td>3% STS</td>
<td>Case series</td>
<td>24</td>
<td>N/A</td>
<td>N/A</td>
<td align="center" colspan="4">N/A</td>
</tr>
<tr>
<td>30</td>
<td>Siniluoto et al<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup>
</td>
<td>1997</td>
<td>Sweden</td>
<td>3% STS</td>
<td>Case series</td>
<td>38</td>
<td>14/24</td>
<td>N/A</td>
<td>38</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>31</td>
<td>Li et al<sup>
<xref ref-type="bibr" rid="bibr36-1538574413492390">36</xref>
</sup>
</td>
<td>2010</td>
<td>China</td>
<td>5% SM</td>
<td>Case series</td>
<td>13</td>
<td>4/9</td>
<td>46.1</td>
<td>8</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>32</td>
<td>Li et al<sup>
<xref ref-type="bibr" rid="bibr37-1538574413492390">37</xref>
</sup>
</td>
<td>2009</td>
<td>China</td>
<td>5% SM</td>
<td>Case series</td>
<td>23</td>
<td>9/14</td>
<td>0%</td>
<td>8</td>
<td>13</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>33</td>
<td>Spence et al<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup>
</td>
<td>2010</td>
<td>Canada</td>
<td>Bleomycin</td>
<td>Case series</td>
<td>31 with 32 lesions</td>
<td>14/17</td>
<td>N/A</td>
<td>31</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>34</td>
<td>Zhi et al<sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup>
</td>
<td>2008</td>
<td>China</td>
<td>Pingyangmycin</td>
<td>Case series</td>
<td>82</td>
<td>26/56</td>
<td>N/A</td>
<td>82</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>35</td>
<td>Rosbe et al<sup>
<xref ref-type="bibr" rid="bibr40-1538574413492390">40</xref>
</sup>
</td>
<td>2011</td>
<td>USA</td>
<td>3% Sotradecol</td>
<td>Case series</td>
<td>10</td>
<td>6/4</td>
<td>N/A</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1538574413492390">
<p>Abbreviations: H and N, head andneck; M/F, male/female; EO, ethanolamine oleate; MO, monoethanolamine; RCT, randomized controlled trial; POL, polidocanol; STS, sodium tetradecyl sulfate; SM, sodium morrhuate; N/A, not available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There were 1214 patients involved in this review who received sclerotherapy as an independent cure for VMs. Postoperative patients with recurrent or residual disease of VMs were also included. The most common sclerosant was ethanol,<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref><xref ref-type="bibr" rid="bibr7-1538574413492390"/><xref ref-type="bibr" rid="bibr8-1538574413492390"/><xref ref-type="bibr" rid="bibr9-1538574413492390"/><xref ref-type="bibr" rid="bibr10-1538574413492390"/><xref ref-type="bibr" rid="bibr11-1538574413492390"/><xref ref-type="bibr" rid="bibr12-1538574413492390"/><xref ref-type="bibr" rid="bibr13-1538574413492390"/><xref ref-type="bibr" rid="bibr14-1538574413492390"/><xref ref-type="bibr" rid="bibr15-1538574413492390"/><xref ref-type="bibr" rid="bibr16-1538574413492390"/><xref ref-type="bibr" rid="bibr17-1538574413492390"/>–<xref ref-type="bibr" rid="bibr18-1538574413492390">18</xref>
</sup> as shown in <xref ref-type="fig" rid="fig2-1538574413492390">Figure 2</xref>, which was used in 13 studies involving 522 patients, followed by polidocanol<sup>
<xref ref-type="bibr" rid="bibr24-1538574413492390">24</xref><xref ref-type="bibr" rid="bibr25-1538574413492390"/><xref ref-type="bibr" rid="bibr26-1538574413492390"/><xref ref-type="bibr" rid="bibr27-1538574413492390"/><xref ref-type="bibr" rid="bibr28-1538574413492390"/><xref ref-type="bibr" rid="bibr29-1538574413492390"/>–<xref ref-type="bibr" rid="bibr30-1538574413492390">30</xref>
</sup> (7 studies with 163 patients), ethanolamine oleate<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>,<xref ref-type="bibr" rid="bibr19-1538574413492390">19</xref><xref ref-type="bibr" rid="bibr20-1538574413492390"/><xref ref-type="bibr" rid="bibr21-1538574413492390"/>–<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup> (5 studies with 221 patients), and sodium tetradecyl sulfate<sup>
<xref ref-type="bibr" rid="bibr31-1538574413492390">31</xref><xref ref-type="bibr" rid="bibr32-1538574413492390"/>–<xref ref-type="bibr" rid="bibr33-1538574413492390">33</xref>
</sup> (5 studies with 143 patients). Sodium morrhuate<sup>
<xref ref-type="bibr" rid="bibr36-1538574413492390">36</xref>,<xref ref-type="bibr" rid="bibr37-1538574413492390">37</xref>
</sup> was used in 2 studies from the same clinical institution conducted at different times. Pingyangmycin,<sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup> bleomycin,<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup> sotradecol,<sup>
<xref ref-type="bibr" rid="bibr40-1538574413492390">40</xref>
</sup> and monoethanolamine<sup>
<xref ref-type="bibr" rid="bibr23-1538574413492390">23</xref>
</sup> were used in 1 study each.</p>
<fig id="fig2-1538574413492390" position="float">
<label>Figure 2.</label>
<caption>
<p>Proportion of patients with each sclerosant.</p>
</caption>
<graphic xlink:href="10.1177_1538574413492390-fig2.tif"/>
</fig>
<p>The outcomes of each sclerosant were summarized in <xref ref-type="table" rid="table2-1538574413492390">Table 2</xref>. Among the 4 mainstream sclerosants, the patients treated with ethanolamine oleate received the highest cure rate of up to 59.2%, followed by polidocanol (41.6%) and ethanol (27.1%), according to the objective measurement of volume by different means. Meanwhile, the total efficiency of these 4 sclerosants, defined as a more than 25% reduction in the volume, all exceeded 90% except one. Sodium tetradecyl sulfate showed the lowest cure rate (12.0%) and the highest ineffective rate (31.0%). According to the subjective expressions of symptoms and complaints by patients before and after treatments, 66.2% of the patients treated with polidocanol were symptom free at the end of the treatment, and of those treated with ethanol and sodium tetradecyl sulfate, 25% and 16.3%, respectively, were symptom free. The symptoms and complaints included pain, functional disorder, and cosmetic issue. None of the 5 studies on ethanolamine oleate listed the improvements in the clinical symptoms after the treatment.</p>
<table-wrap id="table2-1538574413492390" position="float">
<label>Table 2.</label>
<caption>
<p>Subjective and Objective Outcomes of Each Sclerosing Agent.</p>
</caption>
<graphic alternate-form-of="table2-1538574413492390" xlink:href="10.1177_1538574413492390-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Interventions</th>
<th colspan="4">Objective Outcome (Volume)</th>
<th colspan="4">Subjective Outcome (Symptoms)</th>
</tr>
<tr>
<th>Disappearance N (%)</th>
<th>Improvement N (%)</th>
<th>Little change or Failure N (%)</th>
<th>TNL</th>
<th>Disappearance N (%)</th>
<th>Improvement N (%)</th>
<th>Little change or Failure N (%)</th>
<th>TNPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref><xref ref-type="bibr" rid="bibr7-1538574413492390"/><xref ref-type="bibr" rid="bibr8-1538574413492390"/><xref ref-type="bibr" rid="bibr9-1538574413492390"/><xref ref-type="bibr" rid="bibr10-1538574413492390"/><xref ref-type="bibr" rid="bibr11-1538574413492390"/><xref ref-type="bibr" rid="bibr12-1538574413492390"/><xref ref-type="bibr" rid="bibr13-1538574413492390"/><xref ref-type="bibr" rid="bibr14-1538574413492390"/><xref ref-type="bibr" rid="bibr15-1538574413492390"/><xref ref-type="bibr" rid="bibr16-1538574413492390"/><xref ref-type="bibr" rid="bibr17-1538574413492390"/>–<xref ref-type="bibr" rid="bibr18-1538574413492390">18</xref></sup>
</td>
<td>127 (27.1)</td>
<td>322 (68.8)</td>
<td>19 (4.0)</td>
<td>468</td>
<td>61 (25.0)</td>
<td>171 (70.1)</td>
<td>12 (4.9)</td>
<td>244</td>
</tr>
<tr>
<td>EO<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>,<xref ref-type="bibr" rid="bibr19-1538574413492390">19</xref><xref ref-type="bibr" rid="bibr20-1538574413492390"/><xref ref-type="bibr" rid="bibr21-1538574413492390"/>–<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup>
</td>
<td>132 (59.2)</td>
<td>74 (33.2)</td>
<td>17 (7.6)</td>
<td>223</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>POL<sup>
<xref ref-type="bibr" rid="bibr24-1538574413492390">24</xref><xref ref-type="bibr" rid="bibr25-1538574413492390"/><xref ref-type="bibr" rid="bibr26-1538574413492390"/><xref ref-type="bibr" rid="bibr27-1538574413492390"/><xref ref-type="bibr" rid="bibr28-1538574413492390"/><xref ref-type="bibr" rid="bibr29-1538574413492390"/>–<xref ref-type="bibr" rid="bibr30-1538574413492390">30</xref>
</sup>
</td>
<td>62 (41.6)</td>
<td>74 (49.7)</td>
<td>13 (8.7)</td>
<td>149</td>
<td>53 (66.2)</td>
<td>23 (28.7)</td>
<td>4 (5)</td>
<td>80</td>
</tr>
<tr>
<td>STS<sup>
<xref ref-type="bibr" rid="bibr31-1538574413492390">31</xref><xref ref-type="bibr" rid="bibr32-1538574413492390"/><xref ref-type="bibr" rid="bibr33-1538574413492390"/><xref ref-type="bibr" rid="bibr34-1538574413492390"/>–<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup>
</td>
<td>12 (12.0)</td>
<td>57 (57.0)</td>
<td>31 (31.0)</td>
<td>100</td>
<td>17 (16.3)</td>
<td>61 (58.6)</td>
<td>26 (25.0)</td>
<td>104</td>
</tr>
<tr>
<td>PYMS<sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup>
</td>
<td>0 (0)</td>
<td>79 (96.3)</td>
<td>3 (3.6%)</td>
<td>82</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>SM<sup>
<xref ref-type="bibr" rid="bibr36-1538574413492390">36</xref>,<xref ref-type="bibr" rid="bibr37-1538574413492390">37</xref>
</sup>
</td>
<td>19 (52.7%)</td>
<td>17 (47.2)</td>
<td>0 (0)</td>
<td>36</td>
<td>15 (41.6)</td>
<td>21 (58.3)</td>
<td>0 (0)</td>
<td>36</td>
</tr>
<tr>
<td>Bleomycin<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup>
</td>
<td>0 (0)</td>
<td>21 (58.3)</td>
<td>11 (30.5)</td>
<td>32</td>
<td>0 (0%)</td>
<td>29 (90.6)</td>
<td>3 (9.4)</td>
<td>32</td>
</tr>
<tr>
<td>Sotradecol<sup>
<xref ref-type="bibr" rid="bibr40-1538574413492390">40</xref>
</sup>
</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td>7 (70)</td>
<td>3 (30)</td>
<td align="center">0</td>
<td>10</td>
</tr>
<tr>
<td>MO<sup>
<xref ref-type="bibr" rid="bibr23-1538574413492390">23</xref>
</sup>
</td>
<td>4 (66.7)</td>
<td>2 (33.3)</td>
<td align="center">0</td>
<td>6</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>Total</td>
<td>356 (32.5)</td>
<td>646 (58.9)</td>
<td>94 (8.6)</td>
<td>1096</td>
<td>153 (30.2)</td>
<td>308 (60.9)</td>
<td>45 (8.9)</td>
<td>506</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1538574413492390">
<p>Abbreviations: TNL, total number of lesions; TNPS, total number of patients with symptoms; EO, ethanolamine oleate; POL, polidocanol; STS, sodium tetradecyl sulfate; PYMS, pingyangmycin; SM, sodium morrhuate; MO, monoethanolamine; N/A, not available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Minor and major complications were summarized in <xref ref-type="table" rid="table3-1538574413492390">Table 3</xref>. Skin damage including skin blistering, skin ulcer, skin necrosis, cutaneous fistula, and pigmentation was the most common minor complications with the overall incidence of 10.0%. Among them, the patients treated with ethanol had the highest (15.5%) incidence of skin damage. Other common minor complications after ethanol treatment involved nerve damage (4.8%), muscle fibrosis (1.5%), and transient hemoglobinuria (0.95%). Most cases of nerve damage were reversible. Only 3 cases<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref>,<xref ref-type="bibr" rid="bibr15-1538574413492390">15</xref>
</sup> showed permanent nerve palsy. Two of them were facial nerve palsy and the other was peroneal nerve palsy. One patient<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref>
</sup> had transient facial muscle function but was left with “crocodile tears.” Major complications included 1 case of pulmonary embolism and 1 case of cardiovascular collapse.<sup>
<xref ref-type="bibr" rid="bibr14-1538574413492390">14</xref>
</sup> Pulmonary embolism happened 2 days after sclerotherapy in a patient with a hypercoagulable state. That patient recovered eventually after treatment with no sequelae. Cardiovascular collapse was manifested in the form of acute pulmonary hypertension. After resuscitation and 24-hour stay in the intensive care unit, this patient was discharged home 3 days later.</p>
<table-wrap id="table3-1538574413492390" position="float">
<label>Table 3.</label>
<caption>
<p>Minor and Major Complications of Each Sclerosant.</p>
</caption>
<graphic alternate-form-of="table3-1538574413492390" xlink:href="10.1177_1538574413492390-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th rowspan="2">TNP</th>
<th rowspan="2">Skin Damage N (%)</th>
<th colspan="3">Nerve damage</th>
<th rowspan="2">Muscle Damage N (%)</th>
<th rowspan="2">Renal Damage N (%)</th>
<th rowspan="2">Pulmonary Embolus N (%)</th>
<th rowspan="2">Cardio-vascular Collapse N (%)</th>
<th rowspan="2">Others</th>
</tr>
<tr>
<th>Paresthesia N (%)</th>
<th>Transient Nerve Palsy N (%)</th>
<th>Permanent Nerve Palsy N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref><xref ref-type="bibr" rid="bibr7-1538574413492390"/><xref ref-type="bibr" rid="bibr8-1538574413492390"/><xref ref-type="bibr" rid="bibr9-1538574413492390"/><xref ref-type="bibr" rid="bibr10-1538574413492390"/><xref ref-type="bibr" rid="bibr11-1538574413492390"/><xref ref-type="bibr" rid="bibr12-1538574413492390"/><xref ref-type="bibr" rid="bibr13-1538574413492390"/><xref ref-type="bibr" rid="bibr14-1538574413492390"/><xref ref-type="bibr" rid="bibr15-1538574413492390"/><xref ref-type="bibr" rid="bibr16-1538574413492390"/><xref ref-type="bibr" rid="bibr17-1538574413492390"/>–<xref ref-type="bibr" rid="bibr18-1538574413492390">18</xref>
</sup>
</td>
<td>522</td>
<td>81 (15.5)</td>
<td>10 (1.9)</td>
<td>12 (2.3)</td>
<td>3 (0.57)</td>
<td>8 (1.5)</td>
<td>5 (0.95)</td>
<td>1 (0.19)</td>
<td>1 (0.19)</td>
<td>Crocodile tears(n = 1),<sup>
<xref ref-type="bibr" rid="bibr6-1538574413492390">6</xref>
</sup> reversible ophthalmic venous thrombosis(n = 1)</td>
</tr>
<tr>
<td>EO<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>,<xref ref-type="bibr" rid="bibr19-1538574413492390">19</xref><xref ref-type="bibr" rid="bibr20-1538574413492390"/><xref ref-type="bibr" rid="bibr21-1538574413492390"/>–<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup>
</td>
<td>221</td>
<td>15 (6.7)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>5 (2.3)</td>
<td>35 (15.8)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>POL<sup>
<xref ref-type="bibr" rid="bibr24-1538574413492390">24</xref><xref ref-type="bibr" rid="bibr25-1538574413492390"/><xref ref-type="bibr" rid="bibr26-1538574413492390"/><xref ref-type="bibr" rid="bibr27-1538574413492390"/><xref ref-type="bibr" rid="bibr28-1538574413492390"/><xref ref-type="bibr" rid="bibr29-1538574413492390"/>–<xref ref-type="bibr" rid="bibr30-1538574413492390">30</xref>
</sup>
</td>
<td>163</td>
<td>15 (9.2)</td>
<td>2 (1.2)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>8 (4.9)</td>
<td align="center">–</td>
<td>1 (0.61)</td>
<td align="center">–</td>
</tr>
<tr>
<td>STS<sup>
<xref ref-type="bibr" rid="bibr31-1538574413492390">31</xref><xref ref-type="bibr" rid="bibr32-1538574413492390"/><xref ref-type="bibr" rid="bibr33-1538574413492390"/><xref ref-type="bibr" rid="bibr34-1538574413492390"/>–<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup>
</td>
<td>143</td>
<td>8 (5.6)</td>
<td>7 (4.9)</td>
<td>1 (0.7)</td>
<td align="center">–</td>
<td>1 (0.7)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>Allergy(n = 2),<sup>
<xref ref-type="bibr" rid="bibr33-1538574413492390">33</xref>,<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> gangrene (n = 1),<sup>
<xref ref-type="bibr" rid="bibr34-1538574413492390">34</xref>
</sup> blindness (n = 1),<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> infection (n = 1)<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup>
</td>
</tr>
<tr>
<td>PYMS<sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup>
</td>
<td>82</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>Inflammation(n = 3), <sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup> fever(n = 1)<sup>
<xref ref-type="bibr" rid="bibr39-1538574413492390">39</xref>
</sup>
</td>
</tr>
<tr>
<td>SM<sup>
<xref ref-type="bibr" rid="bibr36-1538574413492390">36</xref>,<xref ref-type="bibr" rid="bibr37-1538574413492390">37</xref>
</sup>
</td>
<td>36</td>
<td>2 (5.5)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>Mild fever(n = 1)<sup>
<xref ref-type="bibr" rid="bibr36-1538574413492390">36</xref>
</sup>
</td>
</tr>
<tr>
<td>Bleomycin<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup>
</td>
<td>31</td>
<td>1 (3.2)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>infection(n = 1),<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup> nausea(n = 2)<sup>
<xref ref-type="bibr" rid="bibr38-1538574413492390">38</xref>
</sup>
</td>
</tr>
<tr>
<td>Sotradecol<sup>
<xref ref-type="bibr" rid="bibr40-1538574413492390">40</xref>
</sup>
</td>
<td>10</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr>
<td>MO<sup>
<xref ref-type="bibr" rid="bibr23-1538574413492390">23</xref>
</sup>
</td>
<td>6</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Total</td>
<td>1214</td>
<td>122</td>
<td align="center">19</td>
<td align="center">13</td>
<td align="center">3</td>
<td align="center">8</td>
<td align="center">48</td>
<td align="center">3</td>
<td align="center">1</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>10.0%</td>
<td>1.5%</td>
<td>0.10%</td>
<td>0.25%</td>
<td>0.66%</td>
<td>3.9%</td>
<td>0.25%</td>
<td>0.08%</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1538574413492390">
<p>Abbreviation: TNP, total number of patients.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Renal damage (15.8%) was the most common complication in the patients treated with ethanolamine oleate, involving 34 cases of hemoglobinuria<sup>
<xref ref-type="bibr" rid="bibr20-1538574413492390">20</xref>,<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>
</sup> and 1 case of renal failure.<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>
</sup> The patient developed acute renal failure with the use of ethanolamine oleate and recovered within 1 week by infusion of K<sup>+</sup>-free fluid and diuretics. Skin damage occurred in 6.7% of the patients. Five patients<sup>
<xref ref-type="bibr" rid="bibr20-1538574413492390">20</xref>,<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup> with lesions on the head and neck experienced trismus. Two<sup>
<xref ref-type="bibr" rid="bibr22-1538574413492390">22</xref>
</sup> of the trismus disappeared after 1 week of conservative management, and the reversibility<sup>
<xref ref-type="bibr" rid="bibr20-1538574413492390">20</xref>
</sup> of the rest was not mentioned in the literature.</p>
<p>Among the patients treated with polidocanol, 15 (9.2%) cases showed skin damage, 8 cases<sup>
<xref ref-type="bibr" rid="bibr25-1538574413492390">25</xref>,<xref ref-type="bibr" rid="bibr29-1538574413492390">29</xref>,<xref ref-type="bibr" rid="bibr30-1538574413492390">30</xref>
</sup> showed transient hemoglobinuria, and 2 (1.2%) cases<sup>
<xref ref-type="bibr" rid="bibr26-1538574413492390">26</xref>
</sup> showed numbness of limbs. One patient<sup>
<xref ref-type="bibr" rid="bibr26-1538574413492390">26</xref>
</sup> experienced decrease in blood pressure and bradyarrhythmia during the treatment and was recovered with fluid replacement and intramuscular injection of atropine sulfate.</p>
<p>For those treated with sodium tetradecyl sulfate, skin damage (5.6%) and nerve damage (5.6%) were the most common complications. All the nerve damage caused by sodium tetradecyl sulfate were reversible, including 7 cases<sup>
<xref ref-type="bibr" rid="bibr34-1538574413492390">34</xref>,<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> of temporary numbness or paresthesias and 1 case<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> of transient slight facial nerve paresis. Allergic reaction was also seen in 2 cases.<sup>
<xref ref-type="bibr" rid="bibr33-1538574413492390">33</xref>,<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> Other rare complications involved 1 case<sup>
<xref ref-type="bibr" rid="bibr34-1538574413492390">34</xref>
</sup> of gangrene of toes, 1 case<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> of unilateral blindness, 1 case<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> of trismus, and 1 case<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> of infection.</p>
</sec>
<sec id="section4-1538574413492390">
<title>Discussion</title>
<p>Venous malformations (VMs) are common congenital vascular malformations that are believed to be the result of faulty embryonic development.<sup>
<xref ref-type="bibr" rid="bibr41-1538574413492390">41</xref>
</sup> They can be seen at birth as well as in childhood or adulthood. Most VMs show progressive enlargement and never regress.</p>
<p>Surgery, once the mainstream treatment for VMs, has been gradually replaced by sclerotherapy for its limits of the functional and esthetic sequelae and the high recurrence rate.<sup>
<xref ref-type="bibr" rid="bibr7-1538574413492390">7</xref>
</sup> However, it cannot be completely eliminated, as surgery is still the only method to remove the residual fibrosis and phleboliths.<sup>
<xref ref-type="bibr" rid="bibr19-1538574413492390">19</xref>
</sup>
</p>
<p>Percutaneous sclerotherapy has been widely used for its unique advantage of being an easy, simple, fast, ambulatory, and low-cost procedure with good tolerability, without the need for hospital admission.<sup>
<xref ref-type="bibr" rid="bibr3-1538574413492390">3</xref>
</sup> A variety of sclerosing agents were described in the literature. Although in our review the patients treated with ethanolamine oleate received the highest cure rate, it is still not possible to make the conclusion that ethanolamine oleate is the most effective sclerosant. Many objective parameters should be taken into account, such as the volume of the lesions and the total number of procedures, for which we failed to extract data in a unified way from the literature, in that they were partially missing or presented in different ways. Symptoms are the other important evaluation criteria of outcome, for they are the main reason on the patients’ attendances. After the sclerotherapy, most of the patients’ symptoms were relieved or disappeared no matter what sclerosant they used.</p>
<p>Among the available sclerosing agents, ethanol seems to be the most powerful according to its side effects and complications. It worked through inducing thrombosis by denaturing blood proteins, denuding the vascular wall of endothelial cells, precipitating their protoplasm, and segmentally fracturing the vascular wall to the level of the internal elastic lamina.<sup>
<xref ref-type="bibr" rid="bibr42-1538574413492390">42</xref>
</sup> Pain and swelling were so common that they happened to all of the patients treated with absolute ethanol. When treating the lesions on the specific area, intubation is required in order to avoid potential breathing difficulties<sup>
<xref ref-type="bibr" rid="bibr16-1538574413492390">16</xref>
</sup> caused by serious swelling. Skin damage, nerve damage, and muscle damage were the main complications. Diluted ethanol was tried to be used in the lesions adjacent to the skin to prevent skin necrosis<sup>
<xref ref-type="bibr" rid="bibr12-1538574413492390">12</xref>
</sup> in 1 study, which seemed to meet with success. This is promising but more studies are needed. Although most of the nerve and muscle damage were reversible in our review, they still should be avoided as much as possible. Tender sclerosants such as polidocanol could take place of ethanol when treating the lesions near the nerves or muscles. Furthermore, controlling the amount of ethanol on each procedure is very important to the safety of patients. That case of cardiovascular collapse happened probably due to the large amount of ethanol injected (1 mL/kg).<sup>
<xref ref-type="bibr" rid="bibr14-1538574413492390">14</xref>
</sup>
</p>
<p>Sodium tetradecyl sulfate seemed to have a potential to trigger allergic reaction. Nerve damage could not be underestimated as well. Apart from 7 cases of temporary numbness or paresthesias and 1 case of transient slight facial nerve paresis, 1 case of monocular blindness was also a result of optic nerve injury probably caused by inflammation and thrombosis of the territory of the malformed ophthalmic vein.<sup>
<xref ref-type="bibr" rid="bibr35-1538574413492390">35</xref>
</sup> Renal damage was the main complication of ethanolamine oleate, recommending that patients with poor renal function must avoid using this sclerosant agent. Polidocanol seemed to be very tender and tolerated, but there was still 1 case of cardiac complication in our review.<sup>
<xref ref-type="bibr" rid="bibr26-1538574413492390">26</xref>
</sup> It was hard to differentiate this reaction from the cause of polidocanol itself or the vasovagal reflux associated with anxiety and pain during puncture. However, the amount of polidocanol should be kept low to prevent this reaction from happening again.</p>
<p>Other sclerosants such as pingyangmycin, sodium morrhuate, bleomycin, sotradecol, and monoethanolamine showed both good efficacy and low complication rates. However, studies on these sclerosant agents were limited and less convincing. More studies on these sclerosants are required.</p>
<p>Several limitations of this review are evident. Most of the studies included were retrospective case series. Only 1 randomized clinical trial was available. There is very limited evidence from randomized clinical trials to support the use of any kind of sclerosants. Besides, data were not always sufficient. Also, this review shows substantial heterogeneity among patients in factors that predict outcomes such as lesion size, lesion location, total number of procedures, and so on. These factors are especially relevant when comparing different sclerosants. In addition, the lack of non-English studies and single database could potentially impact the conclusions.</p>
<p>In conclusion, sclerotherapy is effective for venous malformations. Based on the existing review, it is still hard to figure out which sclerosant is the most effective on VMs. There is a need to lift evidence on sclerotherapy to a higher level by performing randomized controlled trials on the different sclerosants. Furthermore, choosing proper sclerosant according to the patient’s health condition and the lesion’s location may be a potential method to decrease complications.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="equal" id="fn1-1538574413492390">
<label>Authors’ Note</label>
<p>Yajing Qiu and Hui Chen contributed equally to this work and shared “first authorship.”</p>
</fn>
<fn fn-type="conflict" id="fn2-1538574413492390">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1538574413492390">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1538574413492390">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legiehn</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Heran</surname>
<given-names>MK.</given-names>
</name>
</person-group> <article-title>Venous malformations: classification, development, diagnosis, and interventional radiologic management.</article-title> <source>Radiol Clin North Am.</source> <year>2008</year>;<volume>46</volume>(<issue>3</issue>):<fpage>545</fpage>–<lpage>597</lpage>, <fpage>vi</fpage>.</citation>
</ref>
<ref id="bibr2-1538574413492390">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubois</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Soulez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Berthiaume</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lapierre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Therasse</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Soft-tissue venous malformations in adult patients: imaging and therapeutic issues</article-title>. <source>Radiographics</source>. <year>2001</year>;<volume>21</volume>(<issue>6</issue>):<fpage>1519</fpage>–<lpage>1531</lpage>.</citation>
</ref>
<ref id="bibr3-1538574413492390">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Torriani</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hosni</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>D'Avila</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>de Figueiredo</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Sclerotherapy for vascular malformations in the oral and maxillofacial region: treatment and follow-up of 66 lesions</article-title>. <source>J Oral Maxillofac Surg</source>. <year>2011</year>;<volume>69</volume>(<issue>6</issue>):<fpage>e88</fpage>–<lpage>e92</lpage>.</citation>
</ref>
<ref id="bibr4-1538574413492390">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dompmartin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blaizot</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Théron</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations</article-title>. <source>Eur Radiol</source>. <year>2011</year>;<volume>21</volume>(<issue>12</issue>):<fpage>2647</fpage>–<lpage>2656</lpage>.</citation>
</ref>
<ref id="bibr5-1538574413492390">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sannier</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dompmartin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Théron</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>A new sclerosing agent in the treatment of venous malformations. Study on 23 cases.</article-title> <source>Interv Neuroradiol.</source> <year>2004</year>;<volume>10</volume>(<issue>2</issue>):<fpage>113</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr6-1538574413492390">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spence</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krings</surname>
<given-names>T</given-names>
</name>
<name>
<surname>TerBrugge</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy</article-title>. <source>Head Neck</source>. <year>2011</year>;<volume>33</volume>(<issue>1</issue>):<fpage>125</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr7-1538574413492390">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlando</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Caldas</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Nishinari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolosker</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Outpatient percutaneous treatment of deep venous malformations using pure ethanol at low doses under local anesthesia</article-title>. <source>Clinics (Sao Paulo)</source>. <year>2011</year>;<volume>65</volume>(<issue>9</issue>):<fpage>837</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr8-1538574413492390">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baek</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Direct percutaneous alcohol sclerotherapy for venous malformations of head and neck region without fluoroscopic guidance: technical consideration and outcome</article-title>. <source>Neurointervention</source>. <year>2011</year>;<volume>6</volume>(<issue>2</issue>):<fpage>84</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr9-1538574413492390">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Absolute ethanol sclerotherapy for venous malformations in the face and neck</article-title>. <source>J Oral Maxillofac Surg</source>. <year>2010</year>;<volume>68</volume>(<issue>7</issue>):<fpage>1622</fpage>–<lpage>1627</lpage>.</citation>
</ref>
<ref id="bibr10-1538574413492390">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlando</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Caldas</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Nishinari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolosker</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Ethanol sclerotherapy of superficial venous malformation: a new procedure</article-title>. <source>Dermatology</source>. <year>2010</year>;<volume>220</volume>(<issue>4</issue>):<fpage>376</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr11-1538574413492390">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ierardi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Mangini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vaghi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cazzulani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carrafiello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mattassi</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Sclerotherapy of peripheral venous malformations: a new technique to prevent serious complications</article-title>. <source>Vasc Endovascular Surg</source>. <year>2010</year>;<volume>44</volume>(<issue>4</issue>):<fpage>282</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr12-1538574413492390">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Ethanol sclerotherapy for the management of craniofacial venous malformations: the interim results</article-title>. <source>Korean J Radiol</source>. <year>2009</year>;<volume>10</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr13-1538574413492390">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Direct percutaneous ethanol instillation for treatment of venous malformation in the face and neck</article-title>. <source>Br J Plast Surg</source>. <year>2005</year>;<volume>58</volume>(<issue>8</issue>):<fpage>1073</fpage>–<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr14-1538574413492390">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rimon</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Garniek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galili</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Golan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bensaid</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morag</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Ethanol sclerotherapy of peripheral venous malformations</article-title>. <source>Eur J Radiol</source>. <year>2004</year>;<volume>52</volume>(<issue>3</issue>):<fpage>283</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr15-1538574413492390">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Byun</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Choo</surname>
<given-names>IW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Huh</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Advanced management of venous malformation with ethanol sclerotherapy: mid-term results</article-title>. <source>J Vasc Surg</source>. <year>2003</year>;<volume>37</volume>(<issue>3</issue>):<fpage>533</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr16-1538574413492390">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Eckard</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Brecheisen</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Girod</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Tsue</surname>
<given-names>TT</given-names>
</name>
</person-group>. <article-title>Percutaneous ethanol sclerotherapy of venous malformations of the tongue</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2002</year>;<volume>23</volume>(<issue>5</issue>):<fpage>779</fpage>–<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr17-1538574413492390">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shireman</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vogelzang</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Treatment of venous malformations by direct injection with ethanol</article-title>. <source>J Vasc Surg</source>. <year>1997</year>;<volume>26</volume>(<issue>5</issue>):<fpage>838</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr18-1538574413492390">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berthelsen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fogdestam</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Venous malformations in the face and neck. Radiologic diagnosis and treatment with absolute ethanol</article-title>. <source>Acta Radiol Diagn (Stockh)</source>. <year>1986</year>;<volume>27</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr19-1538574413492390">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoque</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>BK</given-names>
</name>
</person-group>. <article-title>Treatment of venous malformations with ethanolamine oleate: a descriptive study of 83 cases</article-title>. <source>Pediatr Surg Int</source>. <year>2011</year>;<volume>27</volume>(<issue>5</issue>):<fpage>527</fpage>–<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr20-1538574413492390">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaji</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kurita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Experience of sclerotherapy and embolosclerotherapy using ethanolamine oleate for vascular malformations of the head and neck</article-title>. <source>Scand J Plast Reconstr Surg Hand Surg</source>. <year>2009</year>;<volume>43</volume>(<issue>3</issue>):<fpage>126</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr21-1538574413492390">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johann</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Aguiar</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>do Carmo</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Mesquita</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Sclerotherapy of benign oral vascular lesion with ethanolamine oleate: an open clinical trial with 30 lesions</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2005</year>;<volume>100</volume>(<issue>5</issue>):<fpage>579</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr22-1538574413492390">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>Sclerotherapy for congenital lesions in the head and neck</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2004</year>;<volume>131</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr23-1538574413492390">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonan</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Miranda Lde</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>de Paula</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Pego</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Martelli-Junior</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Effectiveness of low flow vascular lesions sclerosis with monoethanolamine: report of six cases</article-title>. <source>Med Oral Patol Oral Cir Bucal</source>. <year>2007</year>;<volume>12</volume>(<issue>7</issue>):<fpage>E524</fpage>–<lpage>E527</lpage>.</citation>
</ref>
<ref id="bibr24-1538574413492390">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaise</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Charavin-Cocuzza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riom</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2011</year>;<volume>41</volume>(<issue>3</issue>):<fpage>412</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr25-1538574413492390">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soejima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations</article-title>. <source>J Vasc Surg</source>. <year>2008</year>;<volume>47</volume>(<issue>3</issue>):<fpage>578</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr26-1538574413492390">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mimura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanazawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Percutaneous sclerotherapy for venous malformations using polidocanol under fluoroscopy</article-title>. <source>Acta Med Okayama</source>. <year>2003</year>;<volume>57</volume>(<issue>5</issue>):<fpage>227</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr27-1538574413492390">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabrera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Garcia-Olmedo</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Redondo</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Treatment of venous malformations with sclerosant in microfoam form</article-title>. <source>Arch Dermatol</source>. <year>2003</year>;<volume>139</volume>(<issue>11</issue>):<fpage>1409</fpage>–<lpage>1416</lpage>.</citation>
</ref>
<ref id="bibr28-1538574413492390">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bandhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sawhney</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Sonographically guided percutaneous sclerosis using 1% polidocanol in the treatment of vascular malformations</article-title>. <source>J Clin Ultrasound</source>. <year>2002</year>;<volume>30</volume>(<issue>7</issue>):<fpage>416</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr29-1538574413492390">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marrocco-Trischitta</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Nicodemi</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Stillo</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Sclerotherapy for venous malformations of the glans penis</article-title>. <source>Urology</source>. <year>2001</year>;<volume>57</volume>(<issue>2</issue>):<fpage>310</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr30-1538574413492390">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Color duplex-guided sclerotherapy for the treatment of venous malformations</article-title>. <source>Dermatol Surg</source>. <year>2000</year>;<volume>26</volume>(<issue>4</issue>):<fpage>323</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr31-1538574413492390">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krokidis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Venetucci</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hatzidakis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iaccarino</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Sodium tetradecyl sulphate direct intralesional sclerotherapy of venous malformations of the vulva and vagina: report of five cases</article-title>. <source>Cardiovasc Intervent Radiol</source>. <year>2011</year>;<volume>34</volume>(<issue>suppl 2</issue>):<fpage>S228</fpage>–<lpage>S231</lpage>.</citation>
</ref>
<ref id="bibr32-1538574413492390">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khandpur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>VK</given-names>
</name>
</person-group>. <article-title>Utility of intralesional sclerotherapy with 3% sodium tetradecyl sulphate in cutaneous vascular malformations</article-title>. <source>Dermatol Surg</source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>340</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr33-1538574413492390">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Hayeems</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Beecroft</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Simons</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience</article-title>. <source>J Vasc Interv Radiol</source>. <year>2007</year>;<volume>18</volume>(<issue>3</issue>):<fpage>343</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr34-1538574413492390">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahesh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Thulkar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Khazanchi</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Colour duplex ultrasound-guided sclerotherapy: a new approach to the management of patients with peripheral vascular malformations</article-title>. <source>Clin Imaging</source>. <year>2003</year>;<volume>27</volume>(<issue>3</issue>):<fpage>171</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr35-1538574413492390">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siniluoto</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Wikholm</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Fogdestam</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Edstrom</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulphate (sotradecol)</article-title>. <source>Scand J Plast Reconstr Surg Hand Surg</source>. <year>1997</year>;<volume>31</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr36-1538574413492390">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>YH</given-names>
</name>
</person-group>. <article-title>Digital subtraction angiography-guided foam sclerotherapy of peripheral venous malformations</article-title>. <source>AJR Am J Roentgenol</source>. <year>2010</year>;<volume>194</volume>(<issue>5</issue>):<fpage>W439</fpage>–<lpage>W444</lpage>.</citation>
</ref>
<ref id="bibr37-1538574413492390">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>YH</given-names>
</name>
</person-group>. <article-title>Fluoroscopy-guided foam sclerotherapy with sodium morrhuate for peripheral venous malformations: preliminary experience</article-title>. <source>J Vasc Surg</source>. <year>2009</year>;<volume>49</volume>(<issue>4</issue>):<fpage>961</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr38-1538574413492390">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spence</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krings</surname>
<given-names>T</given-names>
</name>
<name>
<surname>terBrugge</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>da Costa</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Percutaneous sclerotherapy for facial venous malformations: subjective clinical and objective MR imaging follow-up results</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2010</year>;<volume>31</volume>(<issue>5</issue>):<fpage>955</fpage>–<lpage>960</lpage>.</citation>
</ref>
<ref id="bibr39-1538574413492390">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>The role of intralesional Pingyangmycin in the treatment of venous malformation of facial and maxillary region</article-title>. <source>Int J Pediatr Otorhinolaryngol</source>. <year>2008</year>;<volume>72</volume>(<issue>5</issue>):<fpage>593</fpage>–<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr40-1538574413492390">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosbe</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Dowd</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Frieden</surname>
<given-names>IJ</given-names>
</name>
</person-group>. <article-title>Masseteric venous malformations: diagnosis, treatment, and outcomes</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2011</year>;<volume>143</volume>(<issue>6</issue>):<fpage>779</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr41-1538574413492390">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname> Berenguer</surname>
<given-names> B</given-names>
</name>
<name>
<surname> Burrows</surname>
<given-names>PE</given-names>
</name>
<name>
<surname> Zurakowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mulliken</surname>
<given-names> JB</given-names>
</name>
</person-group>. <article-title>Sclerotherapy of craniofacial venous malformations: complications and results.</article-title> <source>Plast Reconstr Surg.</source> <year>1999</year>;<volume>104</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>; <comment>discussion 12-15.</comment>
</citation>
</ref>
<ref id="bibr42-1538574413492390">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasetyono</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Kreshanti</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Efficacy of intra-lesional alcohol injection as alternative and/or complementary treatment of vascular malformations: a systematic review</article-title>. <source>J Plast Reconstr Aesthet Surg</source>. <year>2010</year>;<volume>63</volume>(<issue>7</issue>):<fpage>1071</fpage>–<lpage>1079</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>